Latest news with #MedicalGenetics
Yahoo
3 days ago
- Business
- Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks Consensus Estimate of a loss of $6.4. This compares to a loss of $11.2 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +30.31%. A quarter ago, it was expected that this company would post a loss of $6.8 per share when it actually produced a loss of $5.8, delivering a surprise of +14.71%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Bolt Biotherapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 73.46%. This compares to year-ago revenues of $1.27 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Bolt Biotherapeutics shares have lost about 47.5% since the beginning of the year versus the S&P 500's gain of 10%. What's Next for Bolt Biotherapeutics? While Bolt Biotherapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Bolt Biotherapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$5.70 on $0.9 million in revenues for the coming quarter and -$23.00 on $4.02 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the broader Zacks Medical sector, Electromed, Inc. (ELMD), is yet to report results for the quarter ended June 2025. The results are expected to be released on August 26. This company is expected to post quarterly earnings of $0.22 per share in its upcoming report, which represents a year-over-year change of +10%. The consensus EPS estimate for the quarter has been revised 5% higher over the last 30 days to the current level. Electromed, Inc.'s revenues are expected to be $16.51 million, up 11.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bolt Biotherapeutics, Inc. (BOLT) : Free Stock Analysis Report Electromed, Inc. (ELMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
12-07-2025
- Business
- Yahoo
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Certara, Inc. (CERT), which belongs to the Zacks Medical - Biomedical and Genetics industry. When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 11.54%, on average, in the last two quarters. For the last reported quarter, Certara came out with earnings of $0.14 per share versus the Zacks Consensus Estimate of $0.13 per share, representing a surprise of 7.69%. For the previous quarter, the company was expected to post earnings of $0.13 per share and it actually produced earnings of $0.15 per share, delivering a surprise of 15.38%. With this earnings history in mind, recent estimates have been moving higher for Certara. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Certara currently has an Earnings ESP of +2.44%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on August 6, 2025. When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss. Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Certara, Inc. (CERT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
